2022 ANNUAL REPORT
Tune Therapeutics
Duke researchers found company to mine the new frontier of epigenomics and unlock complex disease.
Duke Capital Partners joins OTC
Duke Capital Partners has moved to be a part of OTC to better integrate into the innovation ecosystem.
Venture Day in Spring 2022
Duke partners with UNC and the NC Biotech Center to put on a university life science startup pitch day for invited investors.
14
This year, we helped
launch a variety of
start-ups – from next-gen animal collars to epigenetic therapeutic platforms.
RETHYMIC receives FDA approval
First ever therapy for congenital athymia, based on licensed Duke research, gets the FDA seal of approval.
Bridgestone invests in Duke start-up Tyrata
Tyrata’s automated tire depth measurement platform continues to drive the industry forward.
Kriya acquires Duke start-up Warden Bio
Gene therapy therapies developed by Duke researchers will continue to be developed for glycogen storage disorders.
New Drug Application for Elacestrant submitted to the FDA
Menarini Group and Radius Health continue to make great progress on a breast cancer therapeutic licensed from Duke.